N-乙基苯乙胺盐酸盐 | 61185-89-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: N-乙基苯乙胺盐酸盐
• 英文名称: ethyl-phenethyl-amine; hydrochloride
• 英文别名: Aethyl-phenaethyl-amin; Hydrochlorid；2-Phenylethyl-ethyl-amine hydrochloride；Ethyl(2-phenylethyl)azanium;chloride；ethyl(2-phenylethyl)azanium;chloride
• CAS: 61185-89-5
• 化学式: C₁₀H₁₅N*ClH
• mdl: MFCD01708197
• 分子量: 185.697
• InChiKey: KEVLAWGGXZKVMF-UHFFFAOYSA-N

物化性质

• 熔点：
  183-184℃

计算性质

• 辛醇/水分配系数(LogP)：
  2.18
• 重原子数：
  12
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  12
• 氢给体数：
  2
• 氢受体数：
  1

安全信息

• 海关编码：
  2921499090

反应信息

• 作为产物：
  描述：

  N-(4-甲氧基苄基)-2-苯基乙胺 在 盐酸 、 偶氮二甲酸二异丙酯 、 polymer-bound triphenylphosphine 作用下， 以 四氢呋喃 、 乙醚 、 二氯甲烷 为溶剂， 生成 N-乙基苯乙胺盐酸盐
  参考文献：
  名称：

  从仲胺高效合成叔胺

  摘要：

  已经开发出可靠的仲胺的N-烷基化。通过使用DIAD和TPP（或PS-TPP），可以使用多种烷基卤将多种仲胺以高至极好的收率转化为相应的叔胺。没有观察到季胺盐的形成。这些方案适用于组合化学文库，也可用于通过可裂解的叔氨基树脂的酸裂解来合成仲胺。

  DOI：

  10.1016/j.tetlet.2006.05.038

文献信息

• Imidazolyl derivatives as corticotropin releasing factor inhibitors
  申请人：——

  公开号：US20020183375A1

  公开（公告）日：2002-12-05

  The present invention relates to novel heterocyclic antagonists of Formula (I) and pharmaceutical compositions comprising said antagonists of the corticotropin releasing factor receptor (“CRF receptor”) 1 useful for the treatment of depression, anxiety, affective disorders, feeding disorders, post-traumatic stress disorder, headache, drug addiction, inflammatory disorders, drug or alcohol withdrawal symptoms and other conditions the treatment of which can be effected by the antagonism of the CRF-1 receptor.

  本发明涉及一种新型杂环拮抗剂，其化学式为(I)，以及包含所述拮抗剂的药物组合物，用于治疗抑郁症、焦虑症、情感障碍、进食障碍、创伤后应激障碍、头痛、药物成瘾、炎症性疾病、药物或酒精戒断症状以及其他可以通过拮抗CRF-1受体来治疗的病症。
• Catalytic Hydrochlorination System and Process for Manufacturing Vinyl Chloride from Acetylene and Hydrogen Chloride in the Presence of this Catalytic System
  申请人：Petitjean Andre

  公开号：US20100063333A1

  公开（公告）日：2010-03-11

  Catalytic hydrochlorination system comprising at least one amine hydrochloride and at least one group VIII metal compound chosen from the group composed of mixtures of a platinum (IV) compound with tin (II) chloride, mixtures of a platinum (II) compound with triphenylphosphine oxide and mixtures of a palladium (II) compound with triphenylphosphine. This catalytic system is suitable for preparing vinyl chloride by reaction of acetylene with hydrogen chloride.

  催化氢氯化系统包括至少一种胺盐酸盐和至少一种来自以下组成的群体VIII金属化合物的混合物：铂（IV）化合物与氯化亚锡的混合物，铂（II）化合物与三苯基膦氧的混合物以及钯（II）化合物与三苯基膦的混合物。该催化系统适用于通过乙炔和氢氯酸反应制备氯乙烯。
• Substituted azole derivatives as inhibitors of corticotropin releasing factor
  申请人：——

  公开号：US20020161019A1

  公开（公告）日：2002-10-31

  The present invention relates to thiazoles, oxazoles, imidazoles and pharmaceutical compositions comprising said compounds antagonizing the corticotropin releasing factor receptor (“CRF receptor”) and useful for the treatment of depression, anxiety, affective disorders, feeding disorders, post-traumatic stress disorder, headache, drug addiction, inflammatory disorders, drug or alcohol withdrawal symptoms and other conditions the treatment of which can be effected by the antagonism of the CRF-1 receptor.

  本发明涉及噻唑、噁唑、咪唑及含有这些化合物的药物组合物，其拮抗促肾上腺皮质激素释放因子受体（“CRF受体”），并可用于治疗抑郁症、焦虑症、情感障碍、饮食障碍、创伤后应激障碍、头痛、药物成瘾、炎症性疾病、药物或酒精戒断症状和其他可以通过拮抗CRF-1受体来治疗的疾病。
• [EN] SUBSTITUTED AZOLE DERIVATIVES AS INHIBITORS OF CORTICOTROPIN RELEASING FACTOR<br/>[FR] DERIVES D'AZOLE SUBSTITUES EN TANT QU'INHIBITEURS DU FACTEUR DE LIBERATION DE LA CORTICOTROPINE
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2002024200A1

  公开（公告）日：2002-03-28

  The present invention relates to thiazoles, oxazoles, imidazoles and pharmaceutical compositions comprising said compounds antagonizing the corticotropin releasing factor receptor ('CRF receptor') and useful for the treatment of depression, anxiety, affective disorders, feeding disorders, post-traumatic stress disorder, headache, drug addiction, inflammatory disorders, drug or alcohol withdrawal symptoms and other conditions the treatment of which can be affected by the antagonism of the CRF-1 receptor.

  本发明涉及噻唑、噁唑、咪唑及包含该类化合物的药物组合物，其对促肾上腺皮质激素释放因子受体（“CRF受体”）具有拮抗作用，并且可用于治疗抑郁症、焦虑症、情感障碍、进食障碍、创伤后应激障碍、头痛、药物成瘾、炎症性疾病、药物或酒精戒断症状以及其他可能受CRF-1受体拮抗作用影响的疾病的治疗。
• [EN] IMIDAZOLYL DERIVATIVES AS CORTICOTROPIN RELEASING FACTOR INHIBITORS<br/>[FR] DERIVES IMIDAZOLYLES COMME INHIBITEURS DU FACTEUR DE LIBERATION DE LA CORTICOTROPINE
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2002058704A1

  公开（公告）日：2002-08-01

  The present invention relates to novel heterocyclic antagonists of Formula I and pharmaceutical compositions comprising said antagonists of the coticotropin releasing factor receptor ('CRF receptor') (formula), useful for the treatment of depression, anxiety, affective disorders, feeding disorders, post-traumatic stress disorder, headache, drug addiction, inflammatory disorders, drug or alcohol withdrawal symptoms and other conditions the treatment of which can be effected by the antagonism of the CRF-1 receptor.

  本发明涉及公式I的新型杂环拮抗剂和包含所述拮抗剂的药物组合物，该药物组合物对促肾上腺皮质激素释放因子受体（'CRF受体'）具有拮抗作用，用于治疗抑郁症、焦虑症、情感障碍、饮食障碍、创伤后应激障碍、头痛、药物成瘾、炎症性疾病、药物或酒精戒断症状和其他可以通过CRF-1受体的拮抗作用治疗的疾病。